Catalog No.
FHE43422
Species reactivity
Human
Host species
Mouse
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
PE
Applications
FCM
Target
CD158 antigen-like family member A, KIR2DL1, Killer cell immunoglobulin-like receptor 2DL1, Natural killer-associated transcript 1, NKAT-1, MHC class I NK cell receptor, CD158A, p58 natural killer cell receptor clones CL-42/47.11, CD158a, p58.1 MHC class-I-specific NK receptor, NKAT1, p58 NK receptor CL-42/47.11, p58 NK receptor CL-43, NKAT-6, NKAT6, MHC class I NK cell receptor, CD158 antigen-like family member B1, CD158b1, p58 natural killer cell receptor clone CL-43, Natural killer-associated transcript 6, CD158B1, KIR2DL2, Killer cell immunoglobulin-like receptor 2DL2, P58 natural killer cell receptor clones CL-39/CL-17, CD158i, MHC class I NK cell receptor, CD158I, p58 NK receptor CL-39/CL-17, NKAT8, KKA3, NKAT-8, CD158 antigen-like family member I, Killer cell immunoglobulin-like receptor 2DS4, Natural killer-associated transcript 8, KIR2DS4
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Accession
P43626, P43627, P43632
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Stability and Storage
Store at 4°C for 12 months. Protect from light. Do not freeze.
Clone ID
NKVFS1
Note
For research use only.
Changes in the natural killer cell repertoire and function induced by the cancer immune adjuvant candidate IMMUNEPOTENT-CRP., PMID:35381435
Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes., PMID:35411634
Characterization of KIR+ NK cell subsets with a monoclonal antibody selectively recognizing KIR2DL1 and blocking the specific interaction with HLA-C., PMID:35439359
Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas., PMID:35474089
Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL., PMID:35500222
KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target., PMID:35687761
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity., PMID:35768150
KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy., PMID:35933091
Donor selection based on NK alloreactivity for patients with hematological malignancies., PMID:35965181
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome., PMID:36046812
Killer-Cell Immunoglobulin-like Receptor Diversity in an Admixed South American Population., PMID:36139351
Induced CD45 Proximity Potentiates Natural Killer Cell Receptor Antagonism., PMID:36169352
KIR-HLA gene diversities and susceptibility to lung cancer., PMID:36241658
Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy., PMID:36261539
ERAP/HLA-C and KIR Genetic Profile in Couples with Recurrent Implantation Failure., PMID:36293373
HLA-B*27 Heavy Chain Homo-Oligomers Promote the Cytotoxicity of NK Cells via Activation of PI3K/AKT Signaling., PMID:36295572
Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia., PMID:36319065
Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell-mediated antitumor immunity., PMID:36377656
Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model., PMID:36386885
Software update: Interpreting killer-cell immunoglobulin-like receptors from whole genome sequence data with PING., PMID:36565030
Understanding the killer-cell immunoglobulin like receptor polymorphism in retinoblastoma., PMID:36594723
Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms., PMID:36633682
Malaria-driven expansion of adaptive-like functional CD56-negative NK cells correlates with clinical immunity to malaria., PMID:36696483
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group., PMID:36822669
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial., PMID:36823323
HHLA2 immune-regulatory roles in cancer., PMID:37011487
Influence of killer immunoglobulin-like receptors genes on the recurrence rate of ocular toxoplasmosis in Brazil., PMID:37018796
NK cell defects: implication in acute myeloid leukemia., PMID:37228595
Genotype List String 1.1: Extending the Genotype List String grammar for describing HLA and Killer-cell Immunoglobulin-like Receptor genotypes., PMID:37286192
Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells., PMID:37390222
NK cells from COVID-19 positive patients exhibit enhanced cytotoxic activity upon NKG2A and KIR2DL1 blockade., PMID:37483595
Cattle killer immunoglobulin-like receptor expression on leukocyte subsets suggests functional divergence compared to humans., PMID:37634416
Understanding the heterogeneity of alloreactive natural killer cell function in kidney transplantation., PMID:37732256
Therapeutic Anti-KIR Antibody of 1-7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom., PMID:37762486
HLA-DPB1*13:01 associates with enhanced, and KIR2DS4*001 with diminished protection from developing severe COVID-19., PMID:37850268
Donor aKIR genes influence the risk of EBV and CMV reactivation after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation., PMID:38081622
Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab., PMID:38185735
[ARL67156, a small-molecule CD39 inhibitor, enhances natural killer cell cytotoxicity against gastric cancer cells in vitro and in nude mice]., PMID:38189385
KIR2DS1 and KIR2DL1-C245 Dominantly Repress NK Cell Degranulation Triggered by Monoclonal or Bispecific Antibodies, whereas Education by Uptuning Inhibitory Killer Ig-related Receptors Exerts No Advantage in Ab-dependent Cellular Cytotoxicity., PMID:38240527
Impact of Natural Killer Cell-Associated Factors on Acute Leukemia Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation with αβ T Cell Depletion in a Pediatric Cohort., PMID:38278183
The investigation of killer-cell immunoglobulin-like receptors (KIRs) and their HLA ligands in Iranian patients with myasthenia gravis., PMID:38422742
IFNγ mediates the resistance of tumor cells to distinct NK cell subsets., PMID:38955423
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors., PMID:38993289
HLA and KIR genetic association and NK cells in anti-NMDAR encephalitis., PMID:39050850
Conformational Alterations of the Cell Surface of Monomeric and Dimeric β2m-Free HLA-I (Proto-HLA) May Enable Novel Immune Functions in Health and Disease., PMID:39057057
High-dimensional analysis of NK cells in kidney transplantation uncovers subsets associated with antibody-independent graft dysfunction., PMID:39388279
The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression., PMID:39540437
Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases., PMID:39559361
CD94-driven in vitro expansion of highly functional adaptive NKG2C+ NKG2A- CD57+ NK cells from CMV+ healthy donors., PMID:39958331
Alloreactive adaptive natural killer cells in renal transplantation: potential contribution to allograft microvascular inflammation., PMID:40340029
For research use only. Not for human or drug use.
